The bisphosphonate-ester apornine does not act by inhibiting protein prenylation, but enhances the effects of lovastatin on myeloma cells

The bisphosphonate-ester apornine does not act by inhibiting protein prenylation, but enhances the effects of lovastatin on myeloma cells

Bibliographic Details
Main Authors:	Roelofs, A, Hulley, P, Graham, R, Russell, G, Shipman, C
Format:	Conference item
Published:	2006

Similar Items

Apomine, an inhibitor of HMG-COA-reductase, does not act by inhibiting protein prenylation in human myeloma cells in vitro
by: Roelofs, A, et al.
Published: (2005)

Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells.
by: Roelofs, A, et al.
Published: (2006)

Risedronate, and its phosphonocarboxylate analogue NE10790, both induce apoptosis, but have differential effects on the cell cycle and protein prenylation in human myeloma cells.
by: Roelofs, A, et al.
Published: (2004)

Nitrogen-containing bisphosphonates induce apoptosis in human bone marrow-derived myeloma cells in vitro by inhibiting protein prenylation.
by: Gordon, S, et al.
Published: (1999)

Studies to elucidate the anti-tumor mechanism of action of risedronate in human myeloma cells; Use of an analogue of risedronate reveals the effects of differential inhibition of prenylation
by: Roelofs, A, et al.
Published: (2005)

Novel insights into the anti-tumour mechanism of action of apomine and its synergistic interaction with lovastatin in myeloma cells in vitro
by: Roelofs, A, et al.
Published: (2006)

Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
by: Roelofs, A, et al.
Published: (2007)

Bisphosphonates--mechanisms of action in multiple myeloma.
by: Shipman, C, et al.
Published: (2000)

Anti-tumour activity of bisphosphonates in human myeloma cells.
by: Shipman, C, et al.
Published: (1998)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
by: Shipman, C, et al.
Published: (2000)

Bisphosphonates and in vivo models of multiple myeloma - Reply
by: Shipman, C, et al.
Published: (2001)

Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition.
by: Dunford, J
Published: (2010)

The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
by: Shipman, C, et al.
Published: (1998)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
by: Croucher, P, et al.
Published: (2003)

Targeting a uniquely nonspecific prenyl synthase with bisphosphonates to combat cryptosporidiosis
by: Artz, J, et al.
Published: (2008)

Targeting a uniquely nonspecific prenyl synthase with bisphosphonates to combat cryptosporidiosis.
by: Artz, J, et al.
Published: (2008)

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.
by: Shipman, C, et al.
Published: (1997)

Lovastatin upregulates chondrocyte marker expression in tenocytes
by: Cornell, H, et al.
Published: (2010)

Lovastatin modulates chondrocyte cell cycle and matrix output
by: Cornell, H, et al.
Published: (2008)

Lovastatin-mediated changes in human tendon cells
by: Kuzma-Kuzniarska, M, et al.
Published: (2015)

Lovastatin-Mediated Changes in Human Tendon Cells
by: Kuzma-Kuzniarska, M, et al.
Published: (2015)

Bisphosphonates: Mechanisms of Action
by: Roelofs, A, et al.
Published: (2008)

Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease
by: Wang Jian, et al.
Published: (2005-10-01)

NE10790, a phosphonocarboxylate analogue of risedronate, induces human myeloma cell apoptosis in vitro
by: Roelofs, A, et al.
Published: (2004)

Lovastatin stimulates type II collagen and glycoaminoglycan protein production in bovine articular chondrocytes
by: Gennero, I, et al.
Published: (2004)

Cholesteryl ester storage disease: complex molecular effects of chronic lovastatin therapy.
by: R Levy, et al.
Published: (1992-07-01)

Persistent abnormalities in lipoprotein composition and cholesteryl ester transfer following lovastatin treatment.
by: JD Bagdade, et al.
Published: (1990-07-01)

Inhibition of prenylated KRAS in a lipid environment.
by: Johanna M Jansen, et al.
Published: (2017-01-01)

Prenylated Chalcone 2 Acts as an Antimitotic Agent and Enhances the Chemosensitivity of Tumor Cells to Paclitaxel
by: Joana Fonseca, et al.
Published: (2016-07-01)

Bisphosphonates
by: Bishop, N, et al.
Published: (2013)

Improved lovastatin production by inhibiting (+)-geodin biosynthesis in aspergillus terreus
by: Hasan, Hanan, et al.
Published: (2019)

The pharmacology of bisphosphonates and new insights into their mechanisms of action.
by: Russell, R, et al.
Published: (1999)

P948: REAL-WORLD EVIDENCE OF BISPHOSPHONATES FOR MULTIPLE MYELOMA
by: Maria Nieves Lopez Muñoz, et al.
Published: (2023-08-01)

Bisphosphonates 2006
by: Russell, R
Published: (2006)

Improved methanol-derived lovastatin production through enhancement of the biosynthetic pathway and intracellular lovastatin efflux in methylotrophic yeast
by: Yiqi Liu, et al.
Published: (2018-05-01)

Improvement of agrobiomass quality and lovastatin production for inhibition of methanogenesis by Aspergillus terreus
by: Jahromi, Mohammad Faseleh
Published: (2012)

Transdermal lovastatin enhances fracture repair in rats.
by: Gutierrez, G, et al.
Published: (2008)

Synthesis of prenylated chalcone /
by: Beh, Gein Khai, 1986-, et al.
Published: (2010)

Regulation of protein prenylation
by: Dominik Jung, et al.
Published: (2023-08-01)

Biochemistry of protein prenylation.
by: PJ Casey
Published: (1992-12-01)